WellDoc, Samsung and OTN launch a pilot for patients with type 2 diabetes
The program will include a minimum of 300 people living with type 2 diabetes who will receive a prescription of BlueStar-S from their healthcare provider.
WellDoc
The company develops mobile solutions to drive behavioral and clinical change in chronic disease. WellDoc’s goal is to improve patient self-management and help physicians overcome gaps in the delivery system to improve clinical outcomes and decrease cost. WellDoc is best known for its flagship product BlueStar, which is a digital therapeutic for adults with type 2 diabetes.